Precigen Gains FDA Orphan Drug Exclusivity for PAPZIMEOS
Money

Precigen Gains FDA Orphan Drug Exclusivity for PAPZIMEOS

authorBy Chika Uwazie
DateJun 20, 2026
Read Time2 min

Precigen Inc., a commercial-stage biopharmaceutical firm, recently achieved a significant milestone by securing Orphan Drug Exclusivity from the U.S. Food and Drug Administration (FDA) for its precision medicine, PAPZIMEOS. This strategic move ensures market exclusivity for the drug until August 2032, effectively preventing the introduction of competing treatments for a seven-year period. This regulatory protection underscores PAPZIMEOS's potential to generate substantial revenue and establishes Precigen's strong position in the treatment landscape for recurrent respiratory papillomatosis (RRP).

PAPZIMEOS, developed through Precigen's innovative AdenoVerse platform, represents a novel approach to combating RRP. The treatment utilizes a modified adenovirus to educate the immune system to specifically target human papillomavirus (HPV) types 6 and 11, which are the primary culprits behind RRP. By addressing the root cause of the condition, PAPZIMEOS aims to significantly reduce the necessity for the repeated surgical interventions traditionally required to manage benign respiratory tumors associated with RRP. The therapy is currently available for commercial use across the United States.

Encouraging long-term clinical trial results, presented at the 2026 ASCO Annual Meeting, further solidified the efficacy of PAPZIMEOS. The data demonstrated sustained effectiveness, with a remarkable 83% of patients who achieved complete response remaining free from surgery for at least 36 months without needing additional treatments. Furthermore, five patients showed no need for further interventions beyond four years, highlighting the drug's enduring benefits and potential to transform the lives of individuals suffering from RRP. This breakthrough in gene and cell therapy signifies a hopeful future for patients seeking less invasive and more durable treatment options.

This achievement by Precigen not only highlights advancements in medical science but also underscores the importance of persistent innovation in addressing unmet medical needs. The successful development and regulatory approval of PAPZIMEOS offer a beacon of hope for patients with RRP, promoting a future where chronic conditions can be managed with greater efficacy and improved quality of life. It serves as a testament to the dedication of researchers and the potential of targeted therapies to bring about transformative changes in healthcare.

More Articles
Money
Ultrapar Participações: A Deep Dive into an Undervalued Stock Under $5
Ultrapar Participações S.A. (UGP) has seen over 22% growth in the past six months, trading at an attractive forward P/E of 8.8. The Canada Pension Plan Investment Board recently acquired a 4.94% stake, highlighting its investment potential without seeking management control. The company's Q1 2026 earnings showed strong adjusted EPS and increased fuel distribution, signaling market recovery and operational efficiency.
By Scott PapeJun 20, 2026
Money
Pagaya Secures Upsized $800 Million Personal Loan ABS Transaction
Pagaya Technologies Ltd. (PGY) successfully closed an oversubscribed $800 million AAA-rated personal loan asset-backed securities (ABS) deal, PAID 2026-4. This transaction attracted 39 institutional investors and marks the third upsized personal loan ABS deal for Pagaya this year, bringing its total year-to-date issuance to nearly $4 billion. The achievement underscores the company's robust funding platform and investor confidence, despite a recent decline in billionaire holdings.
By JL CollinsJun 20, 2026
Money
Energy Infrastructure Fund Delivers Impressive Returns and Stable Income
The First Trust North American Energy Infrastructure Fund (EMLP) continues to provide strong returns and a consistent income stream. With a 19% gain over the past year and a 2.8% yield, EMLP offers investors exposure to North American energy infrastructure through actively managed holdings, including regulated utilities that help mitigate commodity price fluctuations. The fund's strategy focuses on delivering both capital appreciation and steady distributions, making it an attractive option for income-focused investors.
By T. Harv EkerJun 20, 2026
Money
Coupang Inc. Poised for Dominance in South Korean E-commerce Market
Coupang Inc. (CPNG) has received an 'Outperform' rating and a $24 price target from CLSA, highlighting its strong position in South Korea's e-commerce sector. The company's unique first-party logistics network is expected to drive substantial growth, with projections of a 12% compound annual revenue increase and a 30% adjusted EBITDA growth. Coupang, often called the 'Amazon of Korea,' offers comprehensive retail, logistics, streaming, and food delivery services, making it a key player in the market.
By Ramit SethiJun 20, 2026
Money
KKR & Co. Inc. Poised for Growth in AI Infrastructure Sector
KKR & Co. Inc. (KKR) has established Helix Digital Infrastructure with over $10 billion in capital to develop data centers and connectivity for AI. This initiative, supported by key partners like NVIDIA and Vistra, highlights KKR's strategic focus on the expanding AI market and its expertise in managing significant infrastructure assets, positioning it as a notable high-growth large-cap stock for investors.
By Chika UwazieJun 20, 2026